Skip to main content
C

CHIMERIC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · CHM ISIN · AU0000121576 ASX Professional, scientific and technical activities
Open in API
Filings indexed 502 across all filing types
Latest filing 2026-04-26 Regulatory Filings
Country AU Australia
Listing ASX CHM

About CHIMERIC THERAPEUTICS LIMITED

https://www.chimerictherapeutics.com

Chimeric Therapeutics Limited is a clinical-stage cell therapy company focused on the development and commercialization of innovative oncology treatments. The company specializes in chimeric antigen receptor (CAR) T-cell and natural killer (NK) cell therapies designed to target solid tumors and hematologic malignancies. Its lead candidate, CHM 1101 (CLTX CAR T), is a first-in-class therapy utilizing chlorotoxin to target glioblastoma. Additionally, the company is developing CHM 2101, a CDH17-targeted CAR T-cell therapy for gastrointestinal cancers, and the CORE-NK platform, which provides a foundation for off-the-shelf NK cell therapies. By leveraging advanced cellular engineering, Chimeric Therapeutics aims to address significant unmet needs in cancer care through precision medicine and novel therapeutic platforms.

Recent filings

Filing Released Lang Actions
CHM CORE-NK Phase 1B clinical trial achieves 60% CR/CRi 3 pages 212.0KB
Regulatory Filings Classification · 1% confidence The document is an ASX announcement presenting clinical trial results (60% CR/CRi in Phase 1B study). It contains no financial metrics or earnings figures, no board or management changes, no capital or M&A details, and is not an interim or annual report. It is a standard regulatory press release of operational news submitted to the exchange, which does not fit any more specific category. Therefore it falls under the general “Regulatory Filings” fallback category (RNS).
2026-04-26 English
Results of Meeting 2 pages 327.9KB
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an ASX announcement detailing the results of an Extraordinary General Meeting (EGM), including votes cast, proxies received, and whether each resolution was carried. This matches the definition for "Declaration of Voting Results & Voting Rights Announcements" (Code: DVA), which covers official results from shareholder votes at any general meeting.
2026-04-16 English
Update - Consolidation/Split - CHM 5 pages 20.2KB
Share Issue/Capital Change Classification · 1% confidence The document is an Appendix 3A.3 notification to ASX regarding a security consolidation (share consolidation). It details the pre- and post-consolidation numbers, timetable, approvals, and mechanics of the consolidation. This is not an earnings report, management discussion, or regulatory announcement of a report. Instead, it is a capital structure change (share consolidation), which falls under the share issue/capital change category.
2026-04-16 English
Notification of cessation of securities - CHM 4 pages 14.8KB
Regulatory Filings
2026-04-08 English
Investor presentation 18 pages 3.3MB
Regulatory Filings
2026-03-24 English
Prospectus 53 pages 554.8KB
Regulatory Filings
2026-03-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.